Gevorg Yaghjyan/LinkedIn
Apr 2, 2026, 15:52
Gevorg Yaghjyan: How Yale is Redefining Bladder Cancer Treatment Through Strategy Focused Trials
Gevorg Yaghjyan, Former Project Leader at Parexel, shared a post on LinkedIn:
“Clinical trials are evolving from testing drugs to testing strategies.
A new study from Yale School of Medicine in metastatic bladder cancer highlights this shift:
- Systemic therapy (ADC plus immunotherapy)
- Response-based patient selection
- Consolidative surgery in responders
This is not a traditional trial.
It’s a multimodal, adaptive treatment pathway.
From a clinical development perspective, key takeaways:
- Dynamic, response – driven enrollment
- Integration of medical plus surgical oncology
- Increasing operational complexity at site level
- Movement toward strategy – based endpoints
This is where oncology trials are heading:
From molecule-focused – to patient pathway – focused design”
Stay updated with Hemostasis Today.
-
May 20, 2026, 17:10Applications are Now Open for the Fellowship in Clinical Haematology – Apollo Hospitals Navi Mumbai
-
May 20, 2026, 17:02Samantha Pasca and Deanna Maida on the Importance of Registries in Managing Hemophilia in Women
-
May 20, 2026, 16:48New Clinical Resources for Stroke Prevention – Anticoagulation Forum
-
May 20, 2026, 16:39Olivier Christophe: Colocalization of Factor X with Amyloid Light-Chain Deposits
-
May 20, 2026, 15:47Archil Jaliashvili: Hemopure and the Future of Oxygen Delivery in Severe Bleeding
-
May 20, 2026, 15:37Tareq Abadl։ Hemolysis in Blood Bags and Its Dangers in Transfusion
-
May 20, 2026, 15:27Kalyan Roy: Thalassaemia and the Importance of Early Screening
-
May 20, 2026, 15:11Adelard Kakunze: Changing the Future of Sickle Cell Disease in Africa
-
May 20, 2026, 15:00William Aird: When Oxygen Becomes the Limiting Factor